Back

The UNIFLECA study. prospective cohort study on flecainide impact on persistent high premature ventricular contraction burden and induced cardiomyopathy

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: ECG and rhythm monitoring Antiarrhythmic Drug Treatment EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Sotirios Kotoulas

Asklepieion Voulas General Hospital, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Electrocardiographical features in patients with bidirectional ventricular tachycardia
Doctor R. Vazirani Ballesteros (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Lateral wall repolarization in standard ECG as a criterion to democratize conduction system pacing
Doctor D. Fakim (Sherbrooke, CA)
Abstract Slides Video
Presentation thumbnail
QRS-microfragmentation and non-planarity as predictors of clinical outcome and left ventricular ejection fraction improvement following cardiac resychronization therapy
Doctor M. Blondeel (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Rationale and design of the RISC trial: a multicenter RCT to assess in hospital 24 hour observation with telemetry of syncope patients admitted to the cardiac emergency room and emergency department
Mr T. Boel (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Detailed analysis of PAC characteristics in ambulatory ECG data can improve atrial fibrillation risk prediction
Doctor N. Van Vreeswijk (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
ECG and rhythm monitoring

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Flecainide in the treatment of high premature ventricular contractions burden: preliminary results from the UNIFLECA study
thumbnail
Congress Presentation
Efficacy of flecainide in patients with high premature ventricular contractions burden and previous b-blocker failure: a UNIFLECA sub-analysis
thumbnail
Congress Presentation
Efficacy and safety of flecainide in patients with reduced ejection fraction and high premature ventricular complex burden: a single-center experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources